- The patients’ demographic and clinical features.
| Variables | n (%) |
|---|---|
| Age, median year (minimum - maximum) | 9 year (3-17.5) |
| Age groups | |
| ≤5 years old | 11 (21.2) |
| 5-10 years old | 17 (32.7) |
| ≥10 years old | 24 (46.1) |
| Gender | |
| Male | 25 (48.1) |
| Female | 27 (51.9) |
| Nationality | |
| Turkish | 50 (96.2) |
| Refugee | 2 (3.8) |
| Symptom duration, median months (minimum - maximum) | 1 month (1-24) |
| Symptoms | |
| Lymphadenopathy | 52 (100) |
| Fever | 16 (30.8) |
| Weight loss | 13 (25.0) |
| Night sweats | 10 (19.2) |
| Pruritus | 4 (7.7) |
| B symptoms | 22 (42.3) |
| Other clinical features | |
| Bulk disease involvements | 10 (19.2) |
| Splenic | 14 (26.9) |
| Bone | 5 (9.6) |
| Pulmonary | 4 (7.7) |
| Bone marrow | 2 (3.8) |
| Liver | 1 (1.9) |
| Stage | |
| I | 0 (0.0) |
| II | 22 (42.3) |
| III | 24 (46.2) |
| IV | 6 (11.5) |
| Risk group | |
| Low | 15 (28.8) |
| Intermediate | 16 (30.8) |
| High | 21 (40.4) |
| Histologic variant | |
| Classical Hodgkin lymphoma | |
| Nodular sclerosis type | 28 (53.8) |
| Mixed cellularity type | 18 (34.7) |
| Lymphocyte rich type | 1 (1.9) |
| Lymphocyte depleted type | 0 (0.0) |
| Unclassified | 5 (9.6) |
| Chemotherapy regimens | |
| Adriamycin, bleomycin sulfate, vinblastine sulfate, and dacarbazine (ABVD) | 17 (32.7) |
| Oncovin, prednisone, procarbazine hydrochloride, and adriamycin (OPPA) or OEPA + COPP | 14 (26.9) |
| OPPA or oncovin, etoposide phosphate, prednisone, and adriamycin (OEPA) | 7 (13.5) |
| ABVD + cyclophosphamide, oncovin, procarbazine hydrochloride, and prednisone (COPP) | 7 (13.5) |
| ABVD + cyclophosphamide, oncovin, prednisone, and dacarbazine (COPDac) | 6 (11.5) |
| Adriamycin, bleomycin sulfate, vincristine sulfate, etoposide, prednisone, and cyclophosphamide | 1 (1.9) |
Values are presented as a number and (%).